CheckMate 77T

Prespecified interim analysis results from CheckMate 77T trial of neoadjuvant nivolumab or placebo plus chemotherapy and adjuvant nivolumab or placebo in stage II to IIIB NSCLC, as presented at ESMO Congress 2023 and reported by Clinical Care Options (CCO)

Ashwin Mohandas - DM Medical & Haemato-Oncology - Regional Cancer

ESMO Abstract Leak Reveals Promising NSCLC Therapies from BMS

肺癌围术期研究CheckMate-77T报捷，欧狄沃用于可切除肺癌再证疗效医药

Perioperative Opdivo regimen succeeds in non-metastatic NSCLC

Dr. Antonio Calles 🫁🚭 on X: CHECKMATE-77T: Neoadjuvant chemo

Evolution of Combination Therapies for Clinical Stage IIIA Non

PharmaScroll on LinkedIn: Phase 3 Trial Shows Neoadjuvant

CheckMate 77T: Perioperative Immunotherapy in Resectable NSCLC

Canakinumab with and without pembrolizumab in patients with

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer

Ahmed Magdy Rabea on LinkedIn: Thank you IASLC for the amazing

Shaheenah Dawood on LinkedIn: #nsclc #oncologyresearch

CheckMate-77T Trial Meets Primary EFS End Point in Resectable NSCLC

The role of immunotherapy and targeted therapy in the multimodal

News from ESMO - Lung Cancer Research Foundation